Cipla just cracked a $1.5bn U.S. inhaler market. Here’s why it matters
Find out how Cipla’s U.S. FDA approval for generic Ventolin HFA strengthens its respiratory portfolio and inhaler manufacturing strategy.
Pharma & Biotech
Pharma & Biotech
Cipla’s nintedanib approval opens a high-stakes test in the U.S. idiopathic pulmonary fibrosis market
Cipla’s nintedanib approval opens a new chapter in U.S. idiopathic pulmonary fibrosis care. Read what it changes for pricing, access, and competition.